Tumor heterogeneity, tumor microenvironment (TME), and immunological diversity of tumors contribute to the highly complex biology of cancers. When selecting models for preclinical studies in oncology and immuno-oncology (I/O) it is important to consider these complexities to ensure that they are clinically relevant for specific research questions and drug development targets. Each model has its own strengths and limitations, so choosing the most appropriate ones for a study can prove difficult.
In this 15-minute webinar, the first in our Tech Talk series “In Vivo Solutions for Oncology Drug Development,” Dr. Rajendra Kumari provides a guide on what to consider when choosing animal models of oncology and I/O.
Rajendra Kumari, PhD, Global Head of Scientific Communications, Crown Bioscience
After receiving her PhD from the University of Leicester in Molecular Pharmacology, Rajendra joined the Division of Pre-clinical Oncology, School of Clinical Sciences, University of Nottingham as a postdoctoral fellow, building expertise in cancer cell biology, model development, in vitro, in vivo, imaging capabilities, and molecular pharmacology. In 2005, Rajendra took the role of Project & Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit and lecturer/assistant professor in 2008. Rajendra was pivotal in the commercialization of the unit and eventual spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director, and co-founder. Following the merger with Crown Bioscience in 2013, Rajendra led Crown’s European site as CSO & General Manager. In 2018, Rajendra became Global Head of Scientific Communications for all platforms at Crown Inc. Rajendra is a member of the American Association of Cancer Research and British Association of Cancer Research and has authored over 40 abstracts and publications.